Ascendis Pharma (ASND) Q2 2026 Earnings Report

The call conveyed strong commercial momentum and clear early successes: double-digit top-line expansion with EUR 315 million in product revenue, blockbuster-level performance from YORVIPATH (EUR 252 million), a successful SKYTROFA base (>20,000 patients), and a promising early U.S. launch for YUVIWEL with rapid enrollments and reimbursement approvals. Robust clinical readouts (COACH arm-span gains) and progressing partnerships reinforce long-term upside. Offsetting these positives were elevated R&D and SG&A spending, reliance on a one-time PRV sale to bolster reported profit (non-IFRS net profit materially lower at EUR 61 million), and legal/regulatory uncertainties (U.S. IP dispute and confirmatory trial dependence). Overall, highlights outweigh the lowlights given accelerating commercial traction, a strong cash position and no debt, but investors should monitor expense trajectory and the legal/regulatory developments.

The company reiterated near‑term and long‑term guidance alongside its Q2 metrics: Q2 total product revenue was EUR 315m (total revenue EUR 339m, including EUR 24m non‑product collaboration revenue and a EUR 17m milestone), with YORVIPATH EUR 252m, SKYTROFA EUR 55m and newly launched YUVIWEL EUR 8m; Q2 R&D was EUR 76m and SG&A EUR 173m; operating profit was EUR 220m (including EUR 158m PRV sale), non‑IFRS operating profit EUR 92m (27% margin), net profit EUR 207m and non‑IFRS net profit EUR 61m, ending cash EUR 812m after EUR 56m of buybacks, no bank or convertible debt and EUR 1.4bn of equity. For the rest of 2026 management expects YORVIPATH growth “consistent with prior quarters,” relatively stable SKYTROFA U.S. revenue, continuing strong early demand for YUVIWEL (U.S. regulatory decision expected Q4 2026), plans to file at least one IND/CTA per year for new NCEs, anticipates significant operating leverage as revenue scales and reiterates generating greater than EUR 500m of operating cash flow this year while targeting ~EUR 5bn revenue in 2030 and >EUR 10bn over the following decades.